Company / PP&E (Net)
Aligos Therapeutics, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.9M
FY2025
5-year range
$1.9M / $6.2M
FY2021-FY2025
Trend
-21.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $8M in FY2020 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -25.3%.
Declined from $3M to $2M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -27.1%
- 5-Year CAGR
- -25.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aligos Therapeutics, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -25.3%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 21.0% year-over-year.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.9M | -21.0% |
| FY2024 | $2.4M | -27.5% |
| FY2023 | $3.3M | -32.3% |
| FY2022 | $4.8M | -22.1% |
| FY2021 | $6.2M | -22.8% |
| FY2020 | $8.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026